|
AU2006201053A1
|
|
Materials and methods for the treatment of gastroesophageal reflux disease
|
|
CN1950353A
|
|
Materials and methods for treating coagulation disorders
|
|
EP1735296A1
|
|
Materials and methods for treating coagulation disorders
|
|
BRPI0509740A
|
|
compounds for treatment of cardiac arrhythmias and methods of use
|
|
CN1918157A
|
|
Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
|
|
US7256191B2
|
|
Materials and methods for the treatment of depression
|
|
US2004220258A1
|
|
Materials and methods for treating coagulation disorders
|
|
ZA200401945B
|
|
Aryl derivatives for the treatment of diabetes, hyperlipidemia, hypercholesterolemia and atherosclerosis.
|
|
WO2004009594A2
|
|
Xanthine derivatives having adenosine a1-receptor antagonist properties
|
|
EP1465629A1
|
|
5-ht3 receptor antagonists and methods of use
|
|
AU2002361709A1
|
|
Analgesic delivery systems and methods of use
|
|
AU2002360582A1
|
|
Novel compounds for the treatment of cardiac arrhythmia, synthesis, and methods of use
|
|
WO03031415A1
|
|
Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina
|
|
NZ532261A
|
|
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
|
WO03017946A2
|
|
Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
|
|
EP1383756A1
|
|
Coumarin derivatives to be used as anticoagulants
|
|
US6683195B2
|
|
Enantiomeric compounds for treatment of cardiac arrhythmias and methods of use
|
|
EP1414798A2
|
|
Ultrashort-acting opioids for transdermal application
|
|
WO02096855A2
|
|
Anticholinergic compounds and methods of use
|
|
WO0238557A2
|
|
Benzoylbenzofurane derivatives for treatment of cardiac arrhythmia
|
